ASH 2021: a deep dive into ALL immunotherapy

Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation (HSCT). Chimeric antigen receptor (CAR) T-cell therapy consists of modified T cells from patients that target antigens specific to cancer cells. Six CAR T-cell therapies have currently been approved by the FDA, with tisagenlecleucel and brexucabtagene autoleucel approved for B-cell acute lymphoblastic leukemia (B-ALL).

Tune into this podcase as Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, delves into the latest updates in CAR T-cell therapies for B-ALL, including exciting results from the  Phase I BALLI-01 trial (NCT04150497) of UCART22 and a Phase I/IIa trial of PBCAR0191 (NCT03666000). Dr Jain additionally presents preliminary results from a Phase I/II trial of ADCT-602 (NCT03698552), an antibody drug conjugate composed of an anti-CD22 antibody and a pyrrolobenzodiazepine (PBD) dimer cytotoxin. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.